134 related articles for article (PubMed ID: 38861284)
1. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
Ravelo A; Myers K; Brumble R; Bussberg C; Koffman B; Manzoor BS; L Biondo JM; Mansfield C
Future Oncol; 2024 May; ():1-12. PubMed ID: 38861284
[TBL] [Abstract][Full Text] [Related]
2. Patients' priorities in selecting chronic lymphocytic leukemia treatments.
Mansfield C; Masaquel A; Sutphin J; Weiss E; Gutierrez M; Wilson J; Boeri M; Li J; Reyes C
Blood Adv; 2017 Nov; 1(24):2176-2185. PubMed ID: 29296865
[TBL] [Abstract][Full Text] [Related]
3. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Sportoletti P; Laurenti L; Chiarenza A; Gaidano G; Albi E; Mauro FR; Trentin L; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Coscia M; Gozzetti A; Reda G; Caira M; Finsinger P; Gualberti G; Iannella E; Malgieri S; Molica S
Hematol Oncol; 2024 Jan; 42(1):e3216. PubMed ID: 37772620
[TBL] [Abstract][Full Text] [Related]
4. What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment.
Laurenti L; Gaidano G; Mauro FR; Molica S; Pasqualetti P; Scarfò L; Ghia P
Hemasphere; 2022 Sep; 6(9):e771. PubMed ID: 36081648
[TBL] [Abstract][Full Text] [Related]
5. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
Boqué C; Abad MR; Agustín MJ; García-Goñi M; Moreno C; Gabás-Rivera C; Granados E; Castro-Gómez A; Pardo C; Lizán L
J Geriatr Oncol; 2020 Jan; 11(1):24-30. PubMed ID: 30954406
[TBL] [Abstract][Full Text] [Related]
9. Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
Le H; Ryan K; Wahlstrom SK; Maculaitis MC; Will O; Mulvihill E; LeBlanc TW
Patient Prefer Adherence; 2021; 15():99-110. PubMed ID: 33519195
[TBL] [Abstract][Full Text] [Related]
10. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
Landfeldt E; Eriksson J; Ireland S; Musingarimi P; Jackson C; Tweats E; Gaudig M
Leuk Res; 2016 Jan; 40():17-23. PubMed ID: 26654707
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
12. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
13. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
14. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
[TBL] [Abstract][Full Text] [Related]
15. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
Morse AM; Krahn L; Flygare J; Kushida C; Thorpy MJ; Athavale A; Gudeman J
Adv Ther; 2023 Jul; 40(7):3199-3216. PubMed ID: 37243863
[TBL] [Abstract][Full Text] [Related]
16. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
17. Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment.
Lloyd AJ; Gallop K; Ali S; Hughes D; MacCulloch A
Curr Med Res Opin; 2017 Jan; 33(1):23-29. PubMed ID: 27590169
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
20. Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.
Lo SH; Lawrence C; Martí Y; Café A; Lloyd AJ
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):103-115. PubMed ID: 34897574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
